Credit Suisse’s Royalty Pharma RPRX Stock Holding History

Credit Suisse’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,200	Closed	-$561K	–	4518
2020 Q4	$561K	Buy	+11,200	New	+$475K	﹤0.01%	3747

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's RPRX Position: Q1 2024 in Review

Credit Suisse increased its Royalty Pharma (RPRX) stake by 24% in Q1 2024, buying an estimated $5.64M and bringing the position to 994,993 shares worth $30.2M. The position accounts for 0.03% of the portfolio, ranked #522.

Credit Suisse first reported a position in RPRX in Q4 2020 and has held it in 14 quarters since. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

Credit Suisse held 994,993 shares of Royalty Pharma worth $30.2M as of Q1 2024.
Credit Suisse bought 191,288 Royalty Pharma shares in Q1 2024, an estimated $5.64M.
Royalty Pharma made up 0.03% of Credit Suisse's portfolio in Q1 2024, its #522 holding.
Credit Suisse first reported a position in Royalty Pharma in Q4 2020 and has held it in 14 quarters since.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.